Marson CM - Search Results

1

The histone deacetylase inhibitor UCL67022 has potent activity in multiple myeloma and non-Hodgkin lymphoma pre-clinical models.

Maharaj L, Marson CM, Middleton BJ, Rioja AS, Perry J, Oakervee H, Cavenagh J, Joel SP, Popat R. Maharaj L, et al. Among authors: marson cm. Br J Haematol. 2013 Oct;163(1):135-9. doi: 10.1111/bjh.12456. Epub 2013 Jul 9. Br J Haematol. 2013. PMID: 23834265 Free article. No abstract available.

2

Effects of a selection of histone deacetylase inhibitors on mast cell activation and airway and colonic smooth muscle contraction.

Assem el-SK, Peh KH, Wan BY, Middleton BJ, Dines J, Marson CM. Assem el-SK, et al. Among authors: marson cm. Int Immunopharmacol. 2008 Dec 20;8(13-14):1793-801. doi: 10.1016/j.intimp.2008.08.017. Epub 2008 Sep 19. Int Immunopharmacol. 2008. PMID: 18805511

3

Effects of a selection of histone deacetylase inhibitors on antigen- and agonist(s)-induced tracheal smooth muscle contraction.

Assem ES, Peh KH, Wan BY, Dines J, Middleton BJ, Marson CM. Assem ES, et al. Among authors: marson cm. Inflamm Res. 2009 Apr;58 Suppl 1:22-3. doi: 10.1007/s00011-009-0649-7. Inflamm Res. 2009. PMID: 19271130 No abstract available.

4

Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides.

Marson CM, Savy P, Rioja AS, Mahadevan T, Mikol C, Veerupillai A, Nsubuga E, Chahwan A, Joel SP. Marson CM, et al. J Med Chem. 2006 Jan 26;49(2):800-5. doi: 10.1021/jm051010j. J Med Chem. 2006. PMID: 16420064

5

Structure-activity relationships of aryloxyalkanoic acid hydroxyamides as potent inhibitors of histone deacetylase.

Marson CM, Mahadevan T, Dines J, Sengmany S, Morrell JM, Alao JP, Joel SP, Vigushin DM, Charles Coombes R. Marson CM, et al. Bioorg Med Chem Lett. 2007 Jan 1;17(1):136-41. doi: 10.1016/j.bmcl.2006.09.085. Epub 2006 Sep 30. Bioorg Med Chem Lett. 2007. PMID: 17046252

6

Preferential induction of apoptosis of leukaemic cells by farnesol.

Rioja A, Pizzey AR, Marson CM, Thomas NS. Rioja A, et al. Among authors: marson cm. FEBS Lett. 2000 Feb 11;467(2-3):291-5. doi: 10.1016/s0014-5793(00)01168-6. FEBS Lett. 2000. PMID: 10675556 Free article.

7

Histone deacetylase inhibitors: design, structure-activity relationships and therapeutic implications for cancer.

Marson CM. Marson CM. Anticancer Agents Med Chem. 2009 Jul;9(6):661-92. doi: 10.2174/187152009788679976. Anticancer Agents Med Chem. 2009. PMID: 19601748 Review.

8

Stereodefined and polyunsaturated inhibitors of histone deacetylase based on (2E,4E)-5-arylpenta-2,4-dienoic acid hydroxyamides.

Marson CM, Serradji N, Rioja AS, Gastaud SP, Alao JP, Coombes RC, Vigushin DM. Marson CM, et al. Bioorg Med Chem Lett. 2004 May 17;14(10):2477-81. doi: 10.1016/j.bmcl.2004.03.012. Bioorg Med Chem Lett. 2004. PMID: 15109636

9

Discovery of potent, isoform-selective inhibitors of histone deacetylase containing chiral heterocyclic capping groups and a N-(2-aminophenyl)benzamide binding unit.

Marson CM, Matthews CJ, Yiannaki E, Atkinson SJ, Soden PE, Shukla L, Lamadema N, Thomas NS. Marson CM, et al. J Med Chem. 2013 Aug 8;56(15):6156-74. doi: 10.1021/jm400634n. Epub 2013 Jul 23. J Med Chem. 2013. PMID: 23829483

10

Mode of action of histone deacetylase inhibitors on mast cell histamine release and colon muscle contraction.

Peh KH, Wan BY, Assem ES, Middleton JB, Dines J, Marson CM. Peh KH, et al. Among authors: marson cm. Inflamm Res. 2009 Apr;58 Suppl 1:24-5. doi: 10.1007/s00011-009-0650-1. Inflamm Res. 2009. PMID: 19271129 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

33 results

Search Page

Filters